In many cases, the latest treatments for hepatitis C virus (HCV) infection are at least 90% effective at curing the infection; however, there still remains a subset of patients who don’t respond to the new medications. Led by researchers in Germany, a study was conducted to see how ribonucleic acid (RNA) assessment can be used to predict outcomes before the end of treatment.
Therapy options for hepatitis C now include sofosbuvir (SOF), ribavirin (RBV), pegylated-interferon-alfa (PegIFN), simeprevir (SMV), and daclatasvir (DCV). The research team studied 298 patients with hepatitis C, genotypes 1 to 5, treated with the following medication combinations:
- 99 patients: SOF/RBV for 12 or 24 weeks
- 79 patients: SOF/DCV with or without RBV for 12 or 24 weeks
- 69 patients: SOF/SMV with or without RBV for 12 weeks
- 51 patients: PegIFN/SOF/RBV for 12 weeks